Stellaromics

Stellaromics is a biotechnology company at the forefront of 3D in situ multi-omic analysis. The company has developed the Pyxa platform, a technology that facilitates three-dimensional spatial multi-omics to capture the complexity of multicellular tissues. This platform is designed to serve the biomedical research community, with applications in neuroscience and cancer studies.

The company's proprietary STARmap (Spatially-resolved Transcriptome Amplicon-Readout Mapping) technology is a key component of its platform. This technology is capable of measuring the expression of thousands of genes within a single tissue sample, providing researchers with a detailed view of cellular function and organization. By offering a three-dimensional perspective, Stellaromics aims to provide deeper insights than traditional two-dimensional spatial biology methods.

Stellaromics operates on a business model centered around providing its Pyxa platform and associated services to research institutions and pharmaceutical companies. The company generates revenue through the sale of its platform, as well as through collaborations and partnerships with research organizations. The company is backed by venture capital funding, having secured a $25 million series A round to advance its technology and expand its market reach.

Keywords: 3D spatial multi-omics, Pyxa platform, STARmap technology, biomedical research, neuroscience, cancer studies, gene expression, tissue analysis, venture capital, biotechnology